Moreover, the broad potential of SMYD3 inhibition is strengthened by our previous analysis of publicly available human cancer data from The Cancer Genome Atlas (TCGA) dataset indicating that SMYD3 mRNA levels have been found increased in around 30% of colorectal, pancreatic, and breast tumors [20]. This evidence concerns the gene SMYD3 and breast neoplasm.